scholarly journals Henoch-Schönlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Joseph J. LaConti ◽  
Jean A. Donet ◽  
Jeong Hee Cho-Vega ◽  
Daniel A. Sussman ◽  
Dana Ascherman ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Renal Involvement ◽  
Treatment Withdrawal ◽  
Henoch Schonlein Purpura ◽  
Adalimumab Therapy ◽  
Endoscopic Remission ◽  
Adalimumab Treatment ◽  
Inflammatory Bowel ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura

Tumor necrosis factor-α(TNFα) inhibitor therapy has signified an important milestone in the fight against many rheumatological disorders and inflammatory bowel disease (IBD). Cutaneous adverse events caused by this class of medications are well known but relatively uncommon. Most reactions are mild and rarely warrant treatment withdrawal. Henoch-Schönlein purpura (HSP) is a disease with cutaneous vasculitis, arthritis, and gastrointestinal and renal involvement that is usually seen in children, though the worst complications are typically seen in adults. We present a case of HSP complicating adalimumab treatment in a patient with ulcerative colitis who had achieved endoscopic remission. We review similar cases reported in the literature and discuss the consequences of these autoimmune diseases.

Severe Attack of Henoch-Schönlein Purpura With Neurological Involvement During Adalimumab Treatment for Crohn’s Disease

2019 ◽  
Vol 14 (4) ◽  
pp. 538-542 ◽  
Author(s):  
Morgane Condamina ◽  
Emmanuelle Diaz ◽  
Céline Jamart ◽  
Jeffrey Loget ◽  
Anne Durlach ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Treatment Withdrawal ◽  
Neurological Involvement ◽  
Henoch Schonlein Purpura ◽  
Inflammatory Conditions ◽  
Adalimumab Treatment ◽  
Factor Α ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura

Abstract Tumour necrosis factor-α [TNF-α] inhibitors have revolutionised the management of chronic inflammatory conditions. A number of cutaneous adverse events have been reported with TNF inhibition, including vasculitis. Most reactions are mild and rarely warrant treatment withdrawal. Here we describe a patient with Crohn’s disease treated with adalimumab in whom severe multivisceral Henoch-Schönlein purpura developed, including neurological involvement, requiring definitive TNF blocker withdrawal.

scholarly journals 119 Location of skin lesions in Henoch-Schonlein purpura (HSP) and its association with renal involvement

2016 ◽  
Vol 136 (5) ◽  
pp. S22
Author(s):  
J. St. John ◽  
A. Garza-Mayers ◽  
P. Vedak ◽  
M. Hoang ◽  
S. Nigwekar ◽  
...  
Keyword(s):  
Renal Involvement ◽  
Skin Lesions ◽  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura

Location of skin lesions in Henoch-Schönlein purpura and its association with significant renal involvement

2018 ◽  
Vol 78 (1) ◽  
pp. 115-120 ◽  
Author(s):  
Jessica St. John ◽  
Priyanka Vedak ◽  
Anna Cristina Garza-Mayers ◽  
Mai P. Hoang ◽  
Sagar U. Nigwekar ◽  
...  
Keyword(s):  
Renal Involvement ◽  
Skin Lesions ◽  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura

scholarly journals Neutrophil-to-lymphocyte Ratio: A Biomarker for Predicting Systemic Involvement in Henoch–Schonlein Purpura

2021 ◽  
Vol 0 ◽  
pp. 1-4
Author(s):  
Wang Lei ◽  
Shan Yun-Yun ◽  
Xu Ai-E
Keyword(s):  
Inflammatory Marker ◽  
Renal Involvement ◽  
Neutrophil To Lymphocyte Ratio ◽  
Henoch Schonlein Purpura ◽  
Systemic Involvement ◽  
Lymphocyte Ratio ◽  
Number Of Patients ◽  
Pre Treatment ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura

Background: Henoch–Schonlein purpura (HSP) is one of the commonest entities included within the category of cutaneous vasculitis (CV). Our work is purposed to explore the predictive value of neutrophil-to-lymphocyte ratio (NLR) for systemic involvement in Henoch– Schonlein purpura patients. This ratio is known as an inflammatory marker, and is used to assess the systemic inflammation associated with various diseases. Our objective is to establish whether it can be applied for the prediction of renal and gastrointestinal (GI) or purely renal involvement in Henoch–Schonlein purpura. Aim: To determine the relationship between neutrophil-to-lymphocyte ratio and systemic involvement in Henoch–Schonlein purpura Methods: This is a retrospective review of the patients who were diagnosed with Henoch–Schonlein purpura in our hospital between 2012 and 2018. Results: A total of 57 patients met our inclusion criteria. Pre-treatment neutrophil-to-lymphocyte ratio was significantly associated with renal and/or GI manifestations of the disease (p<0.001). The optimal cut-off value of this ratio for predicting systemic involvement was 2.48, with a 95% specificity and a 94% sensitivity. In addition, pretreatment ratio was also found to be significantly correlated with the severity of relevant systemic manifestations of Henoch–Schonlein purpura (r=0.831; p<0.01). Limitations: The small number of patients recruited for our research, its retrospective design, and the inclusion of patients attending the same hospital. Conclusion: This study suggests that neutrophil-to-lymphocyte ratio is suitable as a potential indicator for predicting the systemic involvement in Henoch–Schonlein purpura.

scholarly journals Risk factors for renal involvement and severe kidney disease in 2731 Chinese children with Henoch–Schönlein purpura

Medicine ◽  
2018 ◽  
Vol 97 (38) ◽  
pp. e12520 ◽  
Author(s):  
Ke Wang ◽  
Xiaomei Sun ◽  
Yang Cao ◽  
Liang Dai ◽  
Feiyang Sun ◽  
...  
Keyword(s):  
Risk Factors ◽  
Kidney Disease ◽  
Renal Involvement ◽  
Chinese Children ◽  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura
Sign in / Sign up

Export Citation Format

Share Document